Sharpe ratio
1.06Return earned for the risk taken.
Good
Good risk-adjusted returns. The fund has delivered strong returns for its level of risk.
+25.94%1Y Absolute Return
-0.49%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| ICICI Prudential Nifty Pharma Index Fund - Direct Plan - GrowthFund 3Y annualised return · 5Y history unavailable | ₹13,09,480 | ₹7,32,612 | ₹5,76,868 | +22.68% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.23
₹1 Lakh since launch₹1.23 Lakh
Fund age3.9 yrs
Fund information
Scheme code150930
ISININF109KC11M9
BenchmarkNIFTY Pharma TRI
CategoryOther Scheme - Index Funds
Expense ratio0.51%
Exit loadNil
Minimum SIP₹1,000 SIP
Return comparison
2nd / 1122 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +250.67% | — | — |
| 3M | +35.33% | — | — |
| 6M | +34.73% | — | — |
| 1Y | +25.94% | — | +1.74% |
| 3Y | +22.68% | — | +9.75% |
| Since Launch | +22.64% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
1.61Return earned while limiting downside risk.
Good
Good downside protection with strong returns.
Standard deviation
14.54%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
1.36How well the fund rewarded investors relative to its biggest decline.
Excellent
Excellent balance between returns and drawdowns.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 22 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 21.3307% |
| Divi's Laboratories Ltd | Healthcare | Equity | 10.3593% |
| Cipla Ltd | Healthcare | Equity | 8.3891% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 7.6036% |
| Laurus Labs Ltd | Healthcare | Equity | 7.1512% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 7.0828% |
| Lupin Ltd | Healthcare | Equity | 5.9351% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 4.4264% |
| Alkem Laboratories Ltd | Healthcare | Equity | 3.4046% |
| Glenmark Pharmaceuticals Ltd | Healthcare | Equity | 3.4036% |
Fund management
AS
Ashwini Jemin Bharucha
Since 2024 · Prior to Joining the ICICI Pru Mutual Fund he has worked with ICICI Pru AMC Treasury Mutual Fund Operations,
B.Com , M.Com , Inter CA
VE
Venus Ahuja
Since 2025 · Mr. Venus Ahuja, who was previously part of the Investment Monitoring Team at ICICI AMC, has now been appointed as a Fund Manager and Dealer in the Investments Department of ICICI AMC
Chartered Accountant and B.Com
NI
Nishit Patel
Since 2022 · Prior to joining ICICI Prudential Mutual fund, he has worked with K.K.Dand & Co.
Mr. Patel is a B.Com & Chartered Accountant
Compare similar funds
No comparable category funds are available yet.
Summary
A very high-risk other scheme - index funds fund. Ahead of its category average over 3Y by 12.9 points. Top 10 holdings make up 79% — a handful of stocks can swing returns sharply.
Strengths
- Ahead of its category average over 3Y by 12.9 points.
- Losses and swings stayed contained — worst fall -16.6%, volatility 14.5%.
- Ranks 2 of 1122 in its category over 1 year.
Weaknesses
- Top 10 holdings make up 79% — a handful of stocks can swing returns sharply.
Ideal investor
- Needs a 5+ years horizon to ride out its very high risk level.
- Good fit for SIPs — spreading purchases smooths out 14.5% volatility.
Risk drivers
- Top 10 holdings = 79% of the portfolio.
- Healthcare makes up 100% — trouble in that sector hits the whole fund.